Trastuzumab beyond progression in HER2-positive advanced breast cancer: The Royal Marsden experience

BACKGROUND: Recent UK clinical guidance advises against continuing trastuzumab (T) beyond disease progression (PD) in the absence of brain metastases in patients with HER-2 positive (+ve) advanced breast cancer .We have retrospectively evaluated the outcome of patients with HER-2+ve locally advanced...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Waddell, T, Kotsori, A, Constantinidou, A, Yousaf, N, Ashley, S, Parton, M, Allen, M, Starling, N, Papadopoulos, P, O'Brien, M, Smith, I, Johnston, S
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2011
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3111155/
https://ncbi.nlm.nih.gov/pubmed/21522147
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.138
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados